Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: a study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation.
暂无分享,去创建一个
Adrian Correa | A. Laenkholm | K. Nielsen | D. Commins | D. Hawes | Debra Hawes | Kirsten Vang Nielsen | Roscoe Atkinson | Jens Mollerup | Anne-Vibeke Laenkholm | Mark Verardo | Deborah Commins | Birte Engvad | Charlotte Cort Ehlers | M. Verardo | R. Atkinson | C. Ehlers | A. Correa | J. Mollerup | B. Engvad | Birte Engvad
[1] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[2] K. Bloom,et al. Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. , 2004, American journal of clinical pathology.
[3] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[4] R. Gelber,et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. , 2008, The Lancet. Oncology.
[5] T. Hastie,et al. New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up , 2008, Breast Cancer Research and Treatment.
[6] Matteo Brunelli,et al. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. , 2008, American journal of clinical pathology.
[7] Marta Cuadros,et al. Systematic Review of HER2 Breast Cancer Testing , 2009, Applied immunohistochemistry & molecular morphology : AIMM.
[8] J. Ross,et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.
[9] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.
[10] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[11] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[12] K. Nielsen,et al. Human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.
[13] Gaëtan MacGrogan,et al. Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations , 2009, Modern Pathology.
[14] T. Grogan,et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] John M S Bartlett,et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[17] Mitch Dowsett,et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Arbushites,et al. HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer , 2008, Clinical Cancer Research.
[19] D. Hicks,et al. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. , 2008, American journal of clinical pathology.
[20] H. Yaziji,et al. Begin at the Beginning, With the Tissue!: The Key Message Underlying the ASCO/CAP Task-force Guideline Recommendations for HER2 Testing , 2007, Applied immunohistochemistry & molecular morphology : AIMM.
[21] D. Slamon,et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] P. N. Rao,et al. Her‐2/neu Gene Amplification in Low to Moderately Expressing Breast Cancers: Possible Role of Chromosome 17/Her‐2/neu Polysomy , 2001, The breast journal.
[23] J. Beneke,et al. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. , 2002, American journal of clinical pathology.
[24] Nandini Dendukuri,et al. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis , 2007, Canadian Medical Association Journal.